Cancer

ATNEC – Axillary management in T1-3 N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy

EndoNET – Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women

OPTIMA – Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis

ROSETA – Refining and Optimising a behavioural intervention to Support Endocrine Therapy Adherence: The ROSETA Optimisation Trial

SMALL – A Phase 3, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision

SWEET – Supporting Women with adhErence to hormonE Therapy following breast cancer

ALLTogether1 – A treatment study protocol of the Altogether consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

PETReA – Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma

RADAR – Myeloma XV – Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE)

STATIC – A Randomised Phase III Trial Comparing Intermittent with Continuous Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)

The Molecular Investigation of Unexplained Anaemias – The Molecular Investigation of Unexplained Anaemias and Related Congenital Anaemias

ARIEL – A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild[1]type RAS and right primary tumour location (right-PTL)

FOxTROT Platform – Personalising neo-adjuvant chemotherapy in locally advanced but operable colon cancer. A randomised trial programme

FOxTROT, FOxTROT 2, FOxTROT 3, FOxTROT 4

PemOla – A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/Mb

PRECISION PANC – Advancing personalised medicine treatment strategies for pancreatic cancer

PRIMUS-001 – An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation

TRACC C – Tracking mutations in cell free tumour DNA to predict Relapse in eArly Colorectal Cancer

NHS Cancer Vaccine Launchpad (CVLP)